Protein Biochemistry and Structural Biology Laboratory, National Institute of Malaria Research, Sector-8, Dwarka, New Delhi, India.
Infect Genet Evol. 2011 Jul;11(5):924-33. doi: 10.1016/j.meegid.2011.02.024. Epub 2011 Mar 5.
Plasmodium vivax malaria is a globally widespread disease responsible for 50% of human malaria cases in Central and South America, South East Asia and Indian subcontinent. The rising severity of the disease and emerging resistance of the parasite has emphasized the need for the search of novel therapeutic targets to combat P. vivax malaria. Plasmepsin 4 (PM4) a food vacuole aspartic protease is essential in parasite functions and viability such as initiating hemoglobin digestion and processing of proteins and is being looked upon as potential drug target. Although the plasmepsins of Plasmodium falciparum have been extensively studied, the plasmepsins of P. vivax are not well characterized. This is the first report detailing complete PM4 gene analysis from Indian P. vivax isolates. Blast results of sequences of P. vivax plasmepsin 4 (PvPM4) shows 100% homology among isolates of P. vivax collected from different geographical regions of India. All of the seven Indian isolates did not contain intron within the coding region. Interestingly, PvPM4 sequence analysis showed a very high degree of homology with all other sequences of Plasmodium species available in the genebank. Our results strongly suggest that PvPM4 are highly conserved except a small number of amino acid substitutions that did not modify key motifs at active site formation for the function or the structure of the enzymes. Furthermore, our study shows that PvPM4 occupies unique phylogenetic status within Plasmodium group and sufficiently differ from the most closely related human aspartic protease, cathepsin D. The analysis of 3D model of PM4 showed a typical aspartic protease structure with bi-lobed, compact and distinct peptide binding cleft in both P. vivax and P. falciparum. In order to validate appropriate use of PM4 as potential anti-malarial drug target, studies on genetic and structural variations among P. vivax plasmepsins (PvPMs) from different geographical regions are of utmost importance for drugs and vaccine designs for anti-malarial strategies.
间日疟原虫疟疾是一种在全球范围内广泛传播的疾病,占中美洲和南美洲、东南亚和印度次大陆人类疟疾病例的 50%。该疾病的严重程度不断加剧,寄生虫的抗药性不断增强,这使得人们迫切需要寻找新的治疗靶点来对抗间日疟原虫疟疾。疟原虫半胱氨酸蛋白酶 4(PM4)是一种食物泡天冬氨酸蛋白酶,对寄生虫的功能和生存至关重要,如启动血红蛋白消化和蛋白质加工,因此被视为潜在的药物靶点。虽然恶性疟原虫的疟原虫半胱氨酸蛋白酶已经得到了广泛的研究,但间日疟原虫的疟原虫半胱氨酸蛋白酶还没有得到很好的描述。这是首次详细报道从印度间日疟原虫分离株中分析得到完整的 PM4 基因。对间日疟原虫半胱氨酸蛋白酶 4(PvPM4)的序列进行 Blast 分析结果显示,来自印度不同地理区域的间日疟原虫分离株之间具有 100%的同源性。所有 7 个印度分离株的编码区均不含内含子。有趣的是,PvPM4 序列分析显示与基因库中所有其他疟原虫物种的序列具有非常高的同源性。我们的研究结果强烈表明,除了少数氨基酸取代不会改变酶的活性位点形成的功能或结构的关键模体外,PvPM4 高度保守。此外,我们的研究表明,PvPM4 在疟原虫属内占据独特的系统发育地位,与最密切相关的人类天冬氨酸蛋白酶组织蛋白酶 D 有足够的差异。PM4 的 3D 模型分析显示,在间日疟原虫和恶性疟原虫中均存在典型的天冬氨酸蛋白酶结构,具有双叶、紧凑和明显的肽结合裂隙。为了验证 PM4 作为潜在抗疟药物靶点的适当用途,研究不同地理区域间日疟原虫半胱氨酸蛋白酶(PvPMs)的遗传和结构变异对于抗疟药物和疫苗设计至关重要。